Various macroeconomic and geopolitical concerns have roiled the stock market so far this year. Investors and analysts have been worried about a recession as the Federal Reserve maintains its aggressive stance to tame the surging inflation. The Federal Reserve meets today to hike the benchmark interest rates for the fourth time this year, and Street expects the central bank to…
The Dow Jones Industrial Average rose 0.7% on Wednesday, posting a second straight day’s gain. However, the S&P 500 ended flat, and the tech-heavy Nasdaq Composite slipped 1.2%, as the content giant Netflix Inc. (NFLX) declined some 35% in price in intraday trading on concerns over the company’s loss of subscribers. In addition, the Russia-Ukraine war has created a worldwide crisis…
Over the last week, the S&P 500 is down by 4%. Other than gold and oil, nearly every segment of the market is lower, especially over the last 3 days. We often talk about the importance of interest rates and earnings in terms of equities. And, these do matter the most in the long run. But, a third factor is…
What’s attractive about stocks with a market value around $1 billion? The author of today’s article explains that “At that size, a stock is small enough so that it hasn’t yet been “discovered” by a lot of Wall Street firms, but big enough to have some heft and staying power.” Each year he selects ten stocks hovering around the billion-dollar…
As investors attempt to identify the COVID-19 vaccine stock that will beat all the others, biotech has become one of the hottest sectors, with the S&P Biotech SPDR ETF having jumped nearly 80% since hitting its March low. Today’s article offers an analysis of three specific biotech stocks and insights on what to do with each if you are considering…
When it comes to the S&P 500 and one of the ETFs that represents the overall biotech sector (the iShares Nasdaq Biotechnology ETF), the author of today’s article observes that “the paths of these two investments appear to be diverging.” Given this apparent divergence, he questions whether, despite all the recent medical news, biotech stocks have already had their run.…
Thanks to the economic impact of the coronavirus pandemic, this earnings season may prove to be one of the most unpredictable in a long time. In this environment, a Goldman Sachs strategist advises that the most liquid stocks are likely to outperform – and so he and his team have identified the 13 most liquid S&P 500 stocks. For these…
While analysts at Goldman Sachs believe that the S&P 500 will rise to 3,000 by the end of the year, they also caution that, despite the market having rallied in recent days, more pain lies ahead in the coming weeks and that the market has not hit its coronavirus-induced bottom yet. When can market participants feel confident that the market…
Can you retire on the S&P 500 alone? This is the question that the author of today’s article examines, stating the following: “For investors just starting out and dollar-cost-averaging into their ROTH IRAs or 401ks, an S&P 500 Index Fund can be a good foundational holding. But what about as you age and prepare to retire? Can a well-diversified large…
Three things happened around the time that the last two bear markets began: the 2-to-10-year part of the yield curve inverted briefly, the Federal Reserve cut interest rates for the first time in years, and the S&P 500 peaked in value, before plummeting from that peak. Sound familiar? However, while recession worries are mounting, the author of today’s article argues…